Prazosin
Prazosin, sold under the brand name Minipress among others, is a medication used to treat high blood pressure, symptoms of an enlarged prostate, and nightmares related to post-traumatic stress disorder (PTSD). It is an α1 blocker. It is a less preferred treatment of high blood pressure. Other uses may include heart failure and Raynaud syndrome. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Minipress, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682245 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | α1 blocker |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~60% |
Protein binding | 97% |
Onset of action | 30–90 minutes |
Elimination half-life | 2–3 hours |
Duration of action | 10–24 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.038.971 |
Chemical and physical data | |
Formula | C19H21N5O4 |
Molar mass | 383.408 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include dizziness, sleepiness, nausea, and heart palpitations. Serious side effects may include low blood pressure with standing and depression. Prazosin is a non-selective inverse agonist of the α1-adrenergic receptors. It works to decrease blood pressure by dilating blood vessels and helps with an enlarged prostate by relaxing the outflow of the bladder. How it works in PTSD is not entirely clear.
Prazosin was patented in 1965 and came into medical use in 1974. It is available as a generic medication. In 2020, it was the 190th most commonly prescribed medication in the United States, with more than 2 million prescriptions.